马来酸罗格列酮对2型糖尿病患者心血管危险因素的影响

目的研究马来酸罗格列酮对2型糖尿病患者心血管危险因素C反应蛋白(CRP)、尿微量白蛋白(MAU)、臂踝脉搏波传导速度(baPWV)的影响。方法60例2型糖尿病患者在原有治疗的基础上加用马来酸罗格列酮,加用前及加用治疗6个月后,分别检测空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血三酰甘油(TG)、总胆固醇(TC)、腰/臂比(WHR)、CRP、MAU、baPWV,并比较各指标的变化。结果加用马来酸罗格列酮治疗6个月后,患者FPG、HbA1c、TG、TC、WHR、CRP、MAU、baPWV均下降(P<0.05或P<0.01)。结论马来酸罗格列酮不仅可以改善2型糖尿病者患血糖、血脂代谢,还可以改善2型糖尿病患者的炎症、MAU及动脉硬化。

Influence of rosiglitazone maleate on cardiovascular risk factors in patients with type 2 diabetes

Objective To observe the effect of rosiglitazone maleate on cardiovascular risk factors:C reactive protein(CRP),microalbuminuria(MAU)and brachial-ankle pulse wave velocity(baPWV)in patients with type 2 diabetes.Methods 60 patients with type 2 diabetes were treated with rosiglitazone maleate in addition to their previous treatment.Fast plasma glucose(FPG),HbA1c,triglyceride(TG),total cholesterol(TC),waist-to-hip ratio(WHR),CRP,MAU and baPWV were measured before and after 6 months treated with rosiglitazone maleate.Results The levels of FPG,HbA1c,TG,TC,WHR,CRP,MAU and baPWV decreased significantly after 6 month treated with rosiglitazone maleate treatment(P<0.01 or P<0.05).Conclusion The use of rosiglitazone maleate can not only improve their glucose and lipid metabolism,but also improve the inflammation,microalbuminuria and arteriosclerosis in patients with type 2 diabetes.